key: cord-0860430-ajkprupb
authors: Luetkens, Julian A.; Isaak, Alexander; Öztürk, Can; Mesropyan, Narine; Monin, Malte; Schlabe, Sefan; Reinert, Matthäus; Faron, Anton; Heine, Annkristin; Velten, Markus; Dabir, Darius; Boesecke, Christoph; Strassburg, Christian P.; Attenberger, Ulrike; Zimmer, Sebastian; Duerr, Georg D.; Nattermann, Jacob
title: Cardiac MRI in Suspected Acute COVID-19 Myocarditis
date: 2021-03-04
journal: Radiol Cardiothorac Imaging
DOI: 10.1148/ryct.2021200628
sha: 7dd7071549715e3ed99f64f4703c7bbc1a81b126
doc_id: 860430
cord_uid: ajkprupb

Keywords: COVID-19; coronavirus; myocarditis; cardiac MRI; T1 mapping; T2 mapping

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the resulting coronavirus disease 2019 (COVID-19) has become a worldwide pandemic.

Although primarily affecting the respiratory system, COVID-19 associated myocardial injury is common and can occur directly due to myocardial viral infection or indirectly due to systemic inflammation, endothelial activation, and/or microvascular thrombosis (1, 2) . Beside myocardial infarction, myocardial injury can also be a result of myocardial inflammation (2) . However, current information about associated myocardial inflammation is mainly limited to case reports or series (3) . As cardiac MRI is important for the diagnostic work up of patients with myocarditis, more data about MRI characteristics of COVID-19 associated acute inflammatory injury is needed. The aim of this study was to describe cardiac MRI findings in participants with active COVID-19 infection and suspected acute myocarditis.

The institutional ethics commission approved this prospective study. All participants gave written informed consent. Participants with COVID-19 without structural heart disease and mechanical ventilatory support were included consecutively during the recruitment period from April 2020 to December 2020.

Participants had a clinical suspicion for COVID-19 associated myocarditis with signs of acute myocardial injury (elevated troponin levels with or without electrocardiographic changes). Acute coronary syndromes were excluded by cardiac catheterization. The control groups consisted of healthy volunteers and participants with suspected acute non-COVID-19 myocarditis (4).

Cardiac MRI was performed at 1.5 Tesla in all participants using previously described acquisition parameters (4) . Left ventricular function, average systolic longitudinal strain, T2 signal intensity ratio, T1 relaxation times, T2 relaxation times, extracellular volume, and quantitative late gadolinium enhancement (LGE) were I n p r e s s determined. Focal myocardial edema and LGE were visually assessed. Measurements of the blinded readers (J.A.L. and A.I., with 8 and 4 years of experience, respectively, in cardiac MRI) were conducted as described previously (5) .

Continuous variables between two groups were compared with Student's t test.

χ 2 test was used to compare dichotomous variables. One-way analysis of variance followed by Tukey multiple comparison tests was performed to compare variables in the three participant groups. Statistical significance level was set to P < .05.

Participants with COVID-19 had dyspnea, fever and positive pneumonic infiltrates on chest CT scans or radiographs. Cardiac MRI was performed 7.6 ± 4.6 days after positive reverse transcriptase polymerase chain reaction. C-reactive protein (44.6 ± 37.1 mg/l) and troponin T (114 ± 249 ng/ml) levels were elevated in participants with COVID-19. Participants with COVID-19 had diffuse global higher T1 and T2 relaxation times compared to healthy participants (T1, 1046 ± 45 ms vs 953 ± 32 ms [P < .001];

T2, 61.7 ± 6.6 ms vs 52.9 ± 3.0 ms [P < .001]). Myocardial T1 and T2 were also prolonged in non-COVID-19 myocarditis, but these participants had a more focal disease with more visible myocardial edema (88% [7 of 8] vs. 13% [1 of 8]; P = .003) and

LGE lesions (88% [7 of 8] vs. 38% [3 of 8]; P = .04). The T2 ratio was not significantly elevated in participants with COVID-19 myocarditis, however this was likely secondary to skeletal muscle edema as skeletal muscle T1 was also elevated in participants with COVID myocarditis (Table) . A total of 38% (3 of 8) participants with COVID-19 had severe wall-motion abnormalities consistent with patterns of stressinduced cardiomyopathy (Figure) . Additionally, 38% (3 of 8) of participants with COVID-19 had small pericardial effusions and/or pericardial enhancement.

We found a pattern of diffuse myocardial edema in participants with symptomatic COVID-19 infection and suspected myocarditis. Myocardial edema affects myocardial 52.9 ± 3.0 ‡ § 60.9 ± 4.3 † 61.7 ± 6.6 † < .001 Unless otherwise specified data are means ± standard deviation. P values were obtained using oneway analysis of variance followed by Tukey multiple comparison tests. LGE = late gadolinium enhancement, LVDEV = left ventricular end-diastolic volume, LVEF = left ventricular ejection fraction, RT = relaxation time * Data are absolute frequencies with percentages in parentheses. † P < .05 versus healthy. ‡ P < .05 versus non-COVID-19 myocarditis. § P < .05 versus COVID-19 myocarditis. 

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Myocardial Injury, and Arrhythmia: JACC Focus Seminar

Cardiac Magnetic Resonance Characterization of Myocarditis-Like Acute Cardiac Syndrome in COVID-19

Comparison of Original and 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis: Results of a Validation Cohort

Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis

COVID-19, myocardial edema and dexamethasone